Exelixis reports zanzalintinib new drug application accepted for review by FDA

Exelixis (EXEL) announced that its new drug application for zanzalintinib, in combination with atezolizumab, has been accepted for review in the U.S. for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor therapy. The FDA assigned a standard review with a Prescription Drug User Fee Act target action date of December 3.